• Toremifene Versus Tamoxifen in Advanced Breast Cancer

  2026-08-26

  This Cochrane review synthesized randomized evidence comparing toremifene with tamoxifen in advanced breast cancer and found no clear efficacy advantage for either treatment across response, disease control, progression, or survival outcomes. Its main practical contribution is a structured comparison of endocrine treatment options, while also showing why clinical equivalence should not be confused with identical molecular or tissue-level activity.

• Z-DEVD-FMK Caspase-3 Inhibitor: Practical Guide

  2026-08-26

  Use Z-DEVD-FMK to test whether caspase-dependent execution drives apoptosis, while accounting for its additional calpain activity. This workflow connects melanoma stress assays with neuroprotection models and emphasizes controls that distinguish pathway rescue from nonspecific cytoprotection.

• GDC-0994: ERK1/2 Inhibition Beyond Oncology

  2026-08-25

  A translational perspective on GDC-0994 as an ERK1/2 inhibitor, connecting pathway engagement in RAS-driven cancer models with emerging evidence from estrogen-induced cholestatic injury.

• Phenothiazines, ROS, and Autophagy in Macrophage Defense

  2026-08-25

  Qiu et al. show that phenothiazines strengthen macrophage antibacterial activity through coordinated increases in lysosomal activity, autophagy, and reactive oxygen species. The work supports a host-directed strategy against intracellular bacteria and identifies pharmacological inhibition of autophagy or ROS as evidence that both processes are functionally important.

• SCH772984 HCl: Reliable ERK1/2 Assays

  2026-08-24

  Learn how SCH772984 HCl (SKU B5866) can improve the design and interpretation of cell viability, proliferation, and MAPK signaling experiments. This scenario-based guide connects product specifications with practical controls, dose planning, orthogonal readouts, and recent evidence on APEX2-dependent TERT expression.

• Erlotinib and EGFR–CXCR4 Signaling Complexes

  2026-08-24

  Erlotinib is more than an EGFR kinase inhibitor in cancer research: it can help distinguish receptor phosphorylation from signaling shaped by EGFR–CXCR4 organization. This article translates recent heteromer research into practical assay decisions for pathway, proliferation, and apoptosis studies.

• 2'-O-Methyladenosine in Cell Metabolomics

  2026-08-23

  Learn how to deploy 2'-O-Methyladenosine as an analytical standard and experimental probe in purine metabolism, RNA modification, and nucleoside transport workflows. A measurement-first UHPLC–MS/MS strategy improves sensitivity, separates isomers, and helps distinguish true biology from matrix and handling artifacts.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-08-22

  Song and colleagues show that murine norovirus uses the membrane-rupture protein NINJ1 to release NS1 selectively after caspase-3 processing, while still permitting broad DAMP release. The study combines CRISPR screening, imaging, mutagenesis, biochemical secretion analysis, and mouse infection experiments to connect viral protein export with enteric pathogenesis.

• CUDC-907: Practical Dual-Pathway Workflow

  2026-08-22

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, histone acetylation, cell-cycle behavior, and apoptosis. The supplied record does not include directly matched paper evidence, so the guidance below uses product-dossier specifications and clearly identified workflow recommendations; the compound is not for diagnostic, therapeutic, or clinical use.

• Norovirus Co-opts NINJ1 for Selective NS1 Secretion

  2026-08-21

  This study identifies NINJ1 as a virus-co-opted secretion factor that enables murine norovirus to release the interferon-antagonistic protein NS1 during infection. Combining CRISPR screening, caspase-3 perturbation, imaging, mutagenesis, and mouse infection models, the authors distinguish selective viral cargo release from the broader damage-associated molecular pattern release caused by membrane rupture.

• From Variant Escape to Assay Confidence

  2026-08-20

  Variant evolution is reshaping vaccine research, but broad protection claims are only as persuasive as the antibody measurements supporting them. This thought-leadership guide connects SARS-CoV-2 vaccine immunology with practical assay strategy, showing how HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody can help translational teams move from immune-response observation to reproducible human IgG detection.

• Regorafenib (BAY 73-4506) Assay Guide

  2026-08-20

  A scenario-based laboratory guide to Regorafenib (BAY 73-4506), SKU A8236, for viability, proliferation, migration, invasion, and angiogenesis research. It connects kinase potency, solvent handling, concentration selection, assay interpretation, and vendor-selection decisions to published melanoma findings.

• Cyclopamine: A Hedgehog Signal-to-Phenotype Tool

  2026-08-19

  Cyclopamine is a Hedgehog signaling inhibitor that connects Smoothened perturbation with cancer and developmental phenotypes. This guide explains how comparative genital development research can improve assay design, model selection, and interpretation in cancer research.

• Nocodazole Beyond Cell-Cycle Arrest

  2026-08-19

  Nocodazole is more than a mitotic synchronization reagent: it can expose microtubule-dependent steps in intracellular trafficking and host–pathogen entry. This article translates findings from a Drosophila S2-cell infection study into a rigorous framework for assay design, interpretation, and cross-domain research.

• Regorafenib Suppresses Melanoma Through RRM2

  2026-08-18

  A 2024 iScience study identifies RRM2 as a downstream mediator of Regorafenib activity in melanoma and connects its reduction with impaired proliferation, invasion, metastasis, and increased apoptosis. The work further places the ERK/E2F3 pathway upstream of this response, providing a mechanistic framework for cancer biology research while remaining preclinical.

7691 records 1/513 page Next 12345 下5页 Last page